Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
Adolescent
Adult
Cerebral Cortex
/ diagnostic imaging
Disease Progression
Female
Glatiramer Acetate
/ therapeutic use
Gray Matter
/ diagnostic imaging
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
/ diagnostic imaging
Neuroprotective Agents
/ therapeutic use
Treatment Outcome
Young Adult
Cortical lesions
Glatiramer acetate
Grey matter
Multiple sclerosis
Neuroprotective effect
Regional atrophy
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
17
08
2018
revised:
08
11
2018
accepted:
11
11
2018
pubmed:
20
11
2018
medline:
5
4
2019
entrez:
20
11
2018
Statut:
ppublish
Résumé
In this two year longitudinal study we compare the progression of grey matter (GM) damage in MS patients treated with glatiramer acetate (GA) for relapsing-remitting multiple sclerosis (RRMS) respect to untreated patients. We studied thirty-five treated with GA and thirty-five untreated RRMS subjects matched for age, gender, disease duration and EDSS. Each patient underwent neurological examination every 6 months and 3-Tesla MRI at study entry (T The mean number of new CLs was significantly lower in GA group compared to untreated patients both at T Our findings suggest that GA exerts its immunomodulatory action at the level of GM either reducing the accumulation of CLs and slowing down the GM atrophy progression. Despite a confirmation in a larger sample size is required, our results suggest a possible effect of GA on GM damage.
Identifiants
pubmed: 30453199
pii: S2211-0348(18)30494-2
doi: 10.1016/j.msard.2018.11.009
pii:
doi:
Substances chimiques
Neuroprotective Agents
0
Glatiramer Acetate
5M691HL4BO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
305-311Informations de copyright
Copyright © 2018. Published by Elsevier B.V.